Advertisement
Singapore markets closed

  • Straits Times Index

    3,285.97
    -7.16 (-0.22%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • Dow

    38,460.92
    -42.77 (-0.11%)
     

  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     

  • Bitcoin USD

    64,040.55
    -2,455.23 (-3.69%)
     

  • CMC Crypto 200

    1,365.77
    -16.81 (-1.22%)
     

  • FTSE 100

    8,088.95
    +48.57 (+0.60%)
     

  • Gold

    2,338.70
    +0.30 (+0.01%)
     

  • Crude Oil

    82.85
    +0.04 (+0.05%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • FTSE Bursa Malaysia

    1,569.25
    -2.23 (-0.14%)
     

  • Jakarta Composite Index

    7,155.29
    -19.24 (-0.27%)
     

  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

Is Nektar Therapeutics (NKTR) Stock Outpacing Its Medical Peers This Year?

Zacks Equity Research
Updated
Is (PSEC) Outperforming Other Finance Stocks This Year?

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Nektar Therapeutics (NKTR) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Nektar Therapeutics is one of 757 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. NKTR is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for NKTR's full-year earnings has moved 8.49% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.

ADVERTISEMENT

Based on the most recent data, NKTR has returned 6.35% so far this year. Meanwhile, the Medical sector has returned an average of 6.08% on a year-to-date basis. This shows that Nektar Therapeutics is outperforming its peers so far this year.

Breaking things down more, NKTR is a member of the Medical - Drugs industry, which includes 162 individual companies and currently sits at #111 in the Zacks Industry Rank. On average, stocks in this group have gained 3.55% this year, meaning that NKTR is performing better in terms of year-to-date returns.

Investors with an interest in Medical stocks should continue to track NKTR. The stock will be looking to continue its solid performance.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Nektar Therapeutics (NKTR) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.